Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
BeOne Medicines
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Confirmed diagnosis (per World Health Organization \[WHO\] guidelines, unless otherwise noted) of one of the following:
Cohort A1 and Cohort A2:
1. R/R DLBCL (for Cohort A1 and Cohort A2.1)
* High-grade B-cell lymphomas with translocations of MYC and Bcl-2 and/or Bcl-6 are not allowed in Cohort A1 but may be allowed in Cohort A2.1
2. R/R FL (for Cohort A1 and Cohort A2.2)
3. R/R MZL (for Cohort A1 and Cohort A2.2)
4. Transformed B-cell NHL (for Cohort A1 only)
5. Richter's transformation to DLBCL (for Cohort A1 only)
2. Measurable disease by computed tomography/magnetic resonance imaging.
You may not be if
1. Prior malignancy (other than the disease under study) within the past 2 years, except for curatively treated basal or squamous skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer or lentigo maligna melanoma that has been curatively resected
2. Known central nervous system involvement by lymphoma/leukemia
3. Prior autologous stem cell transplant \< 3 months before the first dose of study drug. Or prior chimeric antigen receptor T-cell (CAR-T) therapy \< 3 months before the first dose of study drug
4. Prior allogeneic stem cell transplant.
5. Major surgery \< 4 weeks before the first dose of study treatment
Clareo Health | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
